Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

6.035 +0.025 (+0.42%)
Streaming Delayed Price Updated: 12:12 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
News headline image
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? ↗
This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Fund Trimmed an $18 Million Stake in Primo Brands Amid a 47% Stock Drop ↗
With shares battered and leverage rising, this quiet trim raises a sharper question about how much patience investors should have left. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year ↗
The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? ↗
Via Stocktwits
MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗
Via Stocktwits
MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗
Via Stocktwits
News headline image
MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗
MannKind (MNKD) Q3 2025 results beat revenue and EPS estimates. The biopharma's shares rose on strong performance and strategic updates, including the scPharmaceuticals acquisition. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗
Via Stocktwits
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗
Via Stocktwits
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’ ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: MannKind's Earnings Forecast ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
MannKind's Earnings Outlook ↗
 
Via Benzinga
News headline image
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish ↗
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion. 
Via Stocktwits
News headline image
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal ↗
MannKind will acquire scPharmaceuticals in a $360 million deal, adding Furoscix and expanding into cardiometabolic care with a $10 billion U.S. market opportunity. 
Via Benzinga
News headline image
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside ↗
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals. 
Via Stocktwits
News headline image
MannKind (MNKD) Q2 Revenue Rises 6% ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market ↗
MannKind Corp (MNKD) missed Q2 2025 revenue and EPS estimates, causing a 3.8% pre-market drop. Despite the miss, strategic moves like Blackstone's $500M financing and product pipeline progress offer... 
Via Chartmill
Topics Earnings
News headline image
Top 3 Health Care Stocks That May Rocket Higher This Quarter ↗
 
Via Benzinga
News headline image
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ ↗
The company significantly reduced its debt principal by $236 million, leaving just $36 million in remaining convertible debt, and ended 2024 with $203 million in cash, cash equivalents, and... 
Via Stocktwits
News headline image
MannKind (MNKD) Q4 2024 Earnings Call Transcript ↗
MNKD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.